HEOR News Roundup

Tuesday, December 17, 2019 | Issue 482

Subscribe Contact Advertise HEOR & RWE Marketplace

Sponsored by

Venture Capitalist Chimes
in on Drug Pricing Debate

Bruce Booth, Atlas Venture partner, offers several suggestions for future drug pricing reform in a recent article published on Forbes.

Read More

NPC Responds to ICER’s Non-Drug Topics for 2020


Article: Organizations Must Balance Cost-Effectiveness Analysis, Patient Centricity


Senate Confirms Hahn to Head FDA


Report Highlights Pharma Trends to Watch for in 2020

 

   Conference

 

Health Economics for Non-Health-Economists

December 17-18 | Brussels, Belgium

 

   Webinar

 

RWE & Regulatory in 21st Century Cures: Where are we and where are we going?

December 17

 
 
Syndicated Reports
   
Pharmacy Benefit Management (PBM) – Industry Size 2019, Market Opportunities, Share Analysis up to 2025
 
Democrats and Drug Pricing
 
White Papers
   
Health Economics in China: Changing Pharmaceutical Pricing and Reimbursement
 
The Growing Influence of the Institute of Clinical and Economic Review on Payer Decisions in the US
 
 
  Sr. Manager Health Economics, Outcomes Research (HEOR), Value Demonstration Associate Director, Health Economics and Outcomes Research (HEOR) Research Manager (PS30792) Senior Director, Life Sciences Pricing and Market Access (focus HEOR)  
 
 
 
 

Share this newsletter!